OXiGENE, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "OXiGENE, Inc. - Product Pipeline Review - 2014" provides data on the OXiGENE, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, OXiGENE, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from OXiGENE, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- OXiGENE, Inc. - Brief OXiGENE, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of OXiGENE, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of OXiGENE, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the OXiGENE, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate OXiGENE, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of OXiGENE, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the OXiGENE, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with OXiGENE, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of OXiGENE, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
OXiGENE, Inc. Snapshot 5
OXiGENE, Inc. Overview 5
Key Information 5
Key Facts 5
OXiGENE, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
OXiGENE, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
OXiGENE, Inc. - Pipeline Products Glance 11
OXiGENE, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
OXiGENE, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
OXiGENE, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
OXiGENE, Inc. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
OXiGENE, Inc. - Drug Profiles 17
fosbretabulin tromethamine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
OXi-4503 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
KGP-156 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
KGP-18 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
KGP-94 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
OXiGENE, Inc. - Pipeline Analysis 26
OXiGENE, Inc. - Pipeline Products by Therapeutic Class 26
OXiGENE, Inc. - Pipeline Products by Target 27
OXiGENE, Inc. - Pipeline Products by Route of Administration 28
OXiGENE, Inc. - Pipeline Products by Molecule Type 29
OXiGENE, Inc. - Pipeline Products by Mechanism of Action 30
OXiGENE, Inc. - Recent Pipeline Updates 31
OXiGENE, Inc. - Dormant Projects 37
OXiGENE, Inc. - Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
OXiGENE, Inc., Key Information 5
OXiGENE, Inc., Key Facts 5
OXiGENE, Inc. - Pipeline by Indication, 2014 8
OXiGENE, Inc. - Pipeline by Stage of Development, 2014 9
OXiGENE, Inc. - Monotherapy Products in Pipeline, 2014 10
OXiGENE, Inc. - Phase III, 2014 11
OXiGENE, Inc. - Phase II, 2014 12
OXiGENE, Inc. - Phase I, 2014 13
OXiGENE, Inc. - Preclinical, 2014 14
OXiGENE, Inc. - Discovery, 2014 15
OXiGENE, Inc. - Unknown, 2014 16
OXiGENE, Inc. - Pipeline by Therapeutic Class, 2014 26
OXiGENE, Inc. - Pipeline by Target, 2014 27
OXiGENE, Inc. - Pipeline by Route of Administration, 2014 28
OXiGENE, Inc. - Pipeline by Molecule Type, 2014 29
OXiGENE, Inc. - Pipeline Products by Mechanism of Action, 2014 30
OXiGENE, Inc. - Recent Pipeline Updates, 2014 31
OXiGENE, Inc. - Dormant Developmental Projects,2014 37